CaTxGNN
Drug repurposing predictions for Health Canada approved medications using TxGNN knowledge graph methods.
Overview
This system analyzes 11,511 Health Canada registered drugs to identify potential new therapeutic uses.
Statistics
| Metric | Value |
|---|---|
| Total Drugs | 11,511 |
| Mapped to DrugBank | 1,254 |
| Mapping Rate | 85.2% |
| Potential Candidates | 21,392,510 |
FHIR API
Access drug repurposing data via FHIR R4 API:
- Capability Statement: /fhir/metadata
- MedicationKnowledge: Drug information with DrugBank mappings
- ClinicalUseDefinition: Predicted therapeutic indications
Data Sources
- Drug Data: Health Canada Drug Product Database (DPD)
- Knowledge Graph: TxGNN
- Drug Identifiers: DrugBank
Disclaimer
This content is for research purposes only. Predictions are computational and have not been validated for clinical use. Always consult healthcare professionals before making any medical decisions.
Contact
- GitHub: yao-care/CaTxGNN
- Website: yao.care
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care, company registration number 83620786, 12F, No. 220, Sec. 2, Taiwan Blvd., West Dist., Taichung City, Taiwan).
CaTxGNN is the Canada site of the company’s “TxGNN Drug Repurposing” product line.
The same system is deployed across 30 countries and regions, each named {CC}TxGNN
(JpTxGNN, UsTxGNN, DETxGNN, and so on) at {cc}txgnn.yao.care.
Product overview: https://www.yao.care/medical/txgnn/.
The TxGNN model itself was developed by the Zitnik Lab at Harvard Medical School and published in Nature Medicine. This platform is the production system 藥提醒科技有限公司 built on top of that model, covering national drug-registration data integration, dual knowledge-graph and deep-learning prediction, PubMed / ClinicalTrials evidence grading, and SMART on FHIR electronic health record integration.